Search

Displaying results 7981 - 7990 of 10000 in total
  1. Drug

    Renvistobart

    go.drugbank.com/drugs/DB19065
    Investigational

    Renvistobart is under investigation in clinical trial NCT02913313 (A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid Tumors).

  2. Drug

    Lerodalcibep

    go.drugbank.com/drugs/DB19071
    ApprovedInvestigational

    Lerodalcibep is a recombinant fusion protein that binds to and inhibits proprotein convertase subtilisin kexin type 9 (PCSK9). … [L54738] Approved by the FDA on December 15, 2025, lerodalcibep is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia

    Categories: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) InhibitorsSynonyms: Engineered binding protein (1-96) anti-(human proprotein convertase subtilisin/kexin type 9), derived from human tenth fibronectin type iii domain, fused via peptidyl linker (97gsgsgs102) to human serum, Protein lib003 (recombinant human proprotein convertase subtilisin/kexin type 9 ligand-binding tenth fibronectin type iii domain) fusion protein with peptide (synthetic 6-amino acid linker) fusion protein
  3. Drug

    TrenibotulinumtoxinE

    go.drugbank.com/drugs/DB19082
    Approved

    and resolve within 2 to 3 weeks. … [L64095] TrenibotulinumtoxinE is distinguished from the serotype A toxins that dominate this setting by its rapid onset and short duration: effects begin around 8 hours after injection, peak at day 7,

    Synonyms: BOTULINUM NEUROTOXIN SEROTYPE E (BONT/E) (EB-001), BONTOXILYSIN-E
  4. Drug

    Oridonin

    go.drugbank.com/drugs/DB19086
    Investigational

    Oridonin is under investigation in clinical trial NCT05130892 (Effect of Inflammasome Inhibitor on Hscrp in Patients After PCI).

    Synonyms: Kaur-16-en-15-one, 7,20-epoxy-1,6,7,14-tetrahydroxy-, (1.alpha.,6.beta.,7.alpha.,14r)-, Kaur-16-en-15-one, 7.alpha.,20-epoxy-1.alpha.,6.beta.,7,14-tetrahydroxy-, (14r)-
  5. Drug

    Modified vaccinia virus Ankara-85A antigen

    go.drugbank.com/drugs/DB19092
    Investigational

    Modified vaccinia virus Ankara-85A antigen is under investigation in clinical trial NCT00953927 (A Study of MVA85A in Healthy Infants).

  6. Drug

    SPH-3127

    go.drugbank.com/drugs/DB19108
    Investigational

    SPH-3127 is under investigation in clinical trial NCT05359068 (Study to Evaluate the Efficacy and Safety of SPH3127 in Patients With Mild-moderate Essential Hypertension).

    Categories: Heterocyclic Compounds, 1-RingSynonyms: CARBAMIC ACID, N-(3-(3-((1R)-1-(CYCLOPROPYL((2R)-2-MORPHOLINYLCARBONYL)AMINO)ETHYL)-6-METHYL-1H-PYRAZOLO(3,4-B)PYRIDIN-1-YL)PROPYL)-, METHYL ESTER
  7. Drug

    KER-047

    go.drugbank.com/drugs/DB19111
    Investigational

    KER-047 is under investigation in clinical trial NCT05927012 (A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (

    Synonyms: QUINOLINE, 7-FLUORO-6-METHOXY-4-(6-(4-(4-METHYL-1-PIPERAZINYL)-1-PIPERIDINYL)PYRAZOLO(1,5-A)PYRIMIDIN-3-YL)-
  8. Drug

    Kisspeptin

    go.drugbank.com/drugs/DB19112
    Investigational

    Kisspeptin is under investigation in clinical trial NCT03315325 (Age-dependent Changes in the Responsiveness of Hypothalamic Pituitary Gonadal Axis in Men).

    Synonyms: Kiss-1 metastasis suppressor
  9. Drug

    Tuparstobart

    go.drugbank.com/drugs/DB19118
    Investigational

    ≥ 1) Recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck). … Tuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS

    Synonyms: INCAGN02385 κ-chain, dimer, Anti-LAG-3 Monoclonal Antibody INCAGN02385
  10. Drug

    Timbetasin

    go.drugbank.com/drugs/DB19119
    Investigational

    Timbetasin is under investigation in clinical trial NCT05555589 (Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2).

    Synonyms: N-ACETYL-L-SERYL-L-ASPARTYL-L-LYSYL-L-PROLYL-L-ASPARTYL-L-METHIONYL-L-ALANYL-L-GLUTAMYL-L-ISOLEUCYL-L-GLUTAMYL-L-LYSYL-L-PHENYLALANYL-L-ASPARTYL-L-LYSYL-L-SERYL-L-LYSYL-L-LEUCYL-L-LYSYL-L-LYSYL-L-THEONYL-L-GLUTAMYL-L-THEONYL-L-GLUTAMINYL-L-GLUTAMYL-L-LYS, L-SERINE, N-ACETYL-L-SERYL-L-.ALPHA.-ASPARTYL-L-LYSYL-L-PROLYL-L-.ALPHA.-ASPARTYL-L-METHIONYL-L-ALANYL-L-.ALPHA.-GLUTAMYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-L-LYSYL-L-PHENYLALANYL-L-.ALPHA.